Agendia to Invest New VC Cash in R&D; Firm Begins Talks with US FDA for MammaPrint Dx | GenomeWeb

Dutch biotech Agendia last week closed a third round of financing with several European backers for an undisclosed amount, and is now in the thick of plans to seek regulatory approval for its MammaPrint test in the US.

Agendia said it has concluded a third financing round, led by Gilde Healthcare and the Van Herk Group. Van Herk, Gilde, AXA Private Equity Venture Funds, Global Life Sciences Ventures, and the Netherlands Cancer Institute are Agendia's current investors.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.